High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Paul Hengeveld; Pieter M. Kolijn; Jeroen A. A. Demmers; Wouter Doff; Julie M. N. Dubois; Melissa Rijken; Jorn Assmann; Lina Van der Straten; Henk-Jan Boiten; Kirsten J. Gussinklo; Peter J. M. Valk; Peter E. Westerweel; Arnon P. Kater; Anton W. Langerak; Mark-David Levin

doi:10.1182/blood-2022-158881

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Paul Hengeveld
, Pieter M. Kolijn
, Jeroen A. A. Demmers
, Wouter Doff
, Julie M. N. Dubois
, Melissa Rijken
, Jorn Assmann
, Lina Van der Straten
, Henk-Jan Boiten
, Kirsten J. Gussinklo
, Peter J. M. Valk
, Peter E. Westerweel
, Arnon P. Kater
, Anton W. Langerak
, Mark-David Levin

Amsterdam UMC

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

Original language	English
Pages (from-to)	9851-9852
Number of pages	2
Journal	Blood
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-158881
Publication status	Published - 15 Nov 2022
Event	64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - New Orleans, Lao People's Democratic Republic Duration: 10 Dec 2022 → 13 Dec 2022

Access to Document

10.1182/blood-2022-158881

Cite this

Hengeveld, P., Kolijn, P. M., Demmers, J. A. A., Doff, W., Dubois, J. M. N., Rijken, M., Assmann, J., Van der Straten, L., Boiten, H.-J., Gussinklo, K. J., Valk, P. J. M., Westerweel, P. E., Kater, A. P., Langerak, A. W., & Levin, M.-D. (2022). High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia. Blood, 140, 9851-9852. https://doi.org/10.1182/blood-2022-158881

@article{63d9c27f5f674c37ad8c07644626297c,

title = "High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia",

author = "Paul Hengeveld and Kolijn, \{Pieter M.\} and Demmers, \{Jeroen A. A.\} and Wouter Doff and Dubois, \{Julie M. N.\} and Melissa Rijken and Jorn Assmann and \{Van der Straten\}, Lina and Henk-Jan Boiten and Gussinklo, \{Kirsten J.\} and Valk, \{Peter J. M.\} and Westerweel, \{Peter E.\} and Kater, \{Arnon P.\} and Langerak, \{Anton W.\} and Mark-David Levin",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-158881",

language = "English",

volume = "140",

pages = "9851--9852",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

note = "64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) ; Conference date: 10-12-2022 Through 13-12-2022",

}

Hengeveld, P , Kolijn, PM, Demmers, JAA, Doff, W, Dubois, JMN, Rijken, M , Assmann, J , Van der Straten, L, Boiten, H-J, Gussinklo, KJ , Valk, PJM, Westerweel, PE, Kater, AP , Langerak, AW & Levin, M-D 2022, 'High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia', Blood, vol. 140, pp. 9851-9852. https://doi.org/10.1182/blood-2022-158881

TY - JOUR

T1 - High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

AU - Hengeveld, Paul

AU - Kolijn, Pieter M.

AU - Demmers, Jeroen A. A.

AU - Doff, Wouter

AU - Dubois, Julie M. N.

AU - Rijken, Melissa

AU - Assmann, Jorn

AU - Van der Straten, Lina

AU - Boiten, Henk-Jan

AU - Gussinklo, Kirsten J.

AU - Valk, Peter J. M.

AU - Westerweel, Peter E.

AU - Kater, Arnon P.

AU - Langerak, Anton W.

AU - Levin, Mark-David

PY - 2022/11/15

Y1 - 2022/11/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000893230302370&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2022-158881

DO - 10.1182/blood-2022-158881

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

SP - 9851

EP - 9852

JO - Blood

JF - Blood

T2 - 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Y2 - 10 December 2022 through 13 December 2022

ER -

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Access to Document

Other files and links

Cite this